Summit Therapeutics Inc.
IPOPublic · Miami, United States · Founded 2003 · $500.0M raised
- Headquarters
- Miami, Florida
- Employees
- 51–200
- Founded
- 2003
- Business Model
- B2B
- Website
- smmttx.com
- Total Funding
- $500.0M
- Last Round
- $500.0M Corporate RoundOct 2025
- Rounds
- 3
- Type
- Public
About
Summit Therapeutics is a biopharmaceutical oncology company focused on discovering and commercializing patient-friendly cancer therapies. Its lead investigational therapy, ivonescimab, is a novel bispecific antibody combining PD-1 and VEGF blockade, currently in multiple Phase 3 clinical trials for non-small cell lung cancer and colorectal cancer. The company licensed ivonescimab from Akeso Inc. in 2023 for the US, Canada, Europe, Japan, and other territories.
Summary
Summit Therapeutics Inc. is a Biotech company based in Miami, United States, founded in 2003. It has raised $500.0M in total across 3 rounds, most recently a $500.0M Corporate Round round in Oct 2025.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...